Quick answer: Nilosigna 200mg (nilotinib) is a targeted capsule for Philadelphia chromosome-positive chronic myeloid leukaemia (CML). Patients swallow it at home on an empty stomach, under the care of a blood cancer specialist. MedHub supplies it on prescription and delivers it to every city in Pakistan.
Nilosigna 200mg is a hard capsule that contains nilotinib, and Oncogen Pharma markets it in Pakistan. Nilotinib belongs to a family of medicines called tyrosine kinase inhibitors. In CML, a faulty gene called BCR-ABL tells the bone marrow to make too many abnormal white cells. Nilotinib switches off the signal from that gene, so blood counts can return towards normal.
Haematologists prescribe Nilosigna 200mg for Philadelphia chromosome-positive CML in two main situations:
Doctors also use nilotinib for children aged one year and older with chronic-phase CML. Your specialist confirms the diagnosis with blood and bone marrow tests, including a test for the BCR-ABL gene, before starting treatment.
You swallow the capsules whole with water, twice a day, roughly 12 hours apart. Food changes how much nilotinib your body absorbs, so you take each dose on an empty stomach, with no food for two hours before and one hour after. Avoid grapefruit and grapefruit juice. Your doctor decides the dose, and your pharmacist explains the timing. Never stop or change it on your own, because CML control depends on taking it every day.
Contact your doctor straight away if you faint, feel your heart racing or beating unevenly, get chest pain, notice pain or coldness in a leg, or have severe pain in the upper abdomen.
Keep the capsules in their original pack below 30°C, away from damp places such as the bathroom. Store them out of the reach of children.
CML treatment runs for years, and many sons and daughters in the UAE, UK and Saudi Arabia arrange each refill of Nilosigna 200mg for a parent back home through MedHub. We also stock the same medicine as Nitonib 200mg (nilotinib) and Nitonib 150mg, along with imatinib such as Imatigliv 400mg. See all our oncology medicines.
Nilosigna 200mg treats Philadelphia chromosome-positive chronic myeloid leukaemia (CML). Doctors use it for newly diagnosed patients and for those whose CML did not respond to imatinib or who could not tolerate it.
Nilosigna 200mg costs Rs 48,000 to Rs 252,550 per pack of 120 capsules. Prices can change with supply, so message us on WhatsApp for today’s price before you order.
Yes. We deliver it across Pakistan, including Islamabad, Rawalpindi, Lahore, Karachi, Peshawar, Multan and Faisalabad.
Yes. Nilotinib is a prescription-only cancer medicine. Share a clear photo of your haematologist’s prescription on WhatsApp, and our pharmacist reviews it before we confirm the order.
You swallow the capsules whole, twice a day, on an empty stomach. Leave two hours without food before each dose and one hour after it. Your doctor sets the dose.
Food, especially a fatty meal, raises the amount of nilotinib in the blood. Higher levels increase the risk of heart rhythm problems, so a fixed fasting window keeps each dose safe and predictable.
Expect regular blood counts, a heart tracing (ECG) and checks on your liver, pancreas, sugar and cholesterol. Your haematologist also measures BCR-ABL levels every few months to see how well the CML is responding.
Yes. Families in the UAE, UK and Saudi Arabia often order through MedHub. Send the prescription on WhatsApp, and our team arranges payment and delivery to your parents’ home or hospital.
Questions about your treatment or outcome? Consult your doctor.
Questions about this medicine, availability or price? Consult our pharmacist on WhatsApp or call 0333 4575527.
Last updated: 3 October 2026
This information is for general awareness only and is not medical advice. Always consult your doctor before starting, stopping or changing any medicine.
| Generic Name | Nilotinib |
|---|---|
| Strength | 200mg |
| Dosage Form | Hard capsules |
| Storage | Below 30°C, protect from moisture |
| Prescription | Prescription only (Rx) |
Reviews
There are no reviews yet.